This analysis examines Indraprastha Medical Corporation Ltd. (INDRAMEDCO) through the lens of its financial statements, valuation metrics, and institutional ownership patterns.
Indraprastha Medical Revenue Trend
Indraprastha Medical Corporation Ltd. clocked ₹1,356 Cr in revenue for FY2025, up 9.0% from FY2024.
The 10-year revenue CAGR of 6.6% reflects steady — if not spectacular — top-line expansion from ₹713 Cr to ₹1,356 Cr.
With a top line of ₹1,356 Cr, Indraprastha Medical Corporation Ltd. operates at a mid-sized scale within the healthcare sector.
Looking at the year-on-year numbers, Indraprastha Medical Corporation Ltd. has seen 4 years of unbroken revenue growth.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,356 Cr | +9.0% |
| FY2024 | ₹1,245 Cr | +13.3% |
| FY2023 | ₹1,099 Cr | +23.7% |
| FY2022 | ₹888 Cr | +44.8% |
| FY2021 | ₹613 Cr | — |
View Indraprastha Medical Corporation Ltd.'s full 10-year revenue trend with CAGR analysis →
Indraprastha Medical Profitability
Year-over-year, net profit grew 29.9% from ₹124 Cr to ₹161 Cr in FY2025 for Indraprastha Medical Corporation Ltd..
A stronger net margin of 11.9% in FY2025 (from 10.0%) points to better profitability per rupee of revenue.
On a per-share basis, diluted earnings were ₹17.56 in FY2025 versus ₹13.52 in FY2024.
Is Indraprastha Medical Undervalued
Indraprastha Medical Corporation Ltd. shares are currently trading at ₹368.90.
Craytheon calculates intrinsic value using the P/E Ratio, DCF, and EPS Growth models. All three appear in the Valuation Models cards below.
Valuation Models
Indraprastha Medical Shareholding Pattern
Promoter holding is steady at 51.0% — no buying or selling over the past 4 quarters.
FII ownership stands at 2.8%, up from the 2.4% recorded a year ago.
As of June 2026, DIIs own 0.6% of the company — down from 3.5% a year earlier.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Jun 2026 | 51.0% | 2.8% | 0.6% | 45.6% |
| Mar 2026 | 51.0% | 2.4% | 0.9% | 45.7% |
| Dec 2025 | 51.0% | 2.7% | 0.8% | 45.4% |
| Sep 2025 | 51.0% | 2.4% | 3.5% | 43.1% |
Track quarterly shareholding changes for Indraprastha Medical Corporation Ltd. →
Indraprastha Medical Balance Sheet
Proportional view as of 3 Aug 2026. Hover blocks for details.
Assets
Liabilities & Equity
In FY2025, the total asset base came in at ₹8.52B, up 17.8% YoY from ₹7.23B.
Property, Plant & Equipment accounts for 38.6% of the total, ahead of Cash & ST Investments (37.8%) and Receivables (8.9%).
Capital structure: 70.1% equity, 3.8% debt, 26.1% operating liabilities. Over the year, debt is down 3.5% and equity is up 24.9%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 3.22B |
| Receivables | 754.50M |
| Inventories | 69.90M |
| Property, Plant & Equipment | 3.29B |
| Investments | 571.20M |
| Intangibles & Goodwill | 5.90M |
| Other Assets | 607.70M |
| Category | Value |
|---|---|
| Equity | 5.97B |
| Short-term Debt | 22.20M |
| Long-term Debt | 305.40M |
| Trade Payables | 1.23B |
| Other Liabilities | 996.40M |
Indraprastha Medical at a Glance
Pulling it all together, here's what the numbers say about Indraprastha Medical Corporation Ltd. (INDRAMEDCO) heading into the next fiscal year.
Revenue of ₹1,356 Cr in FY2025, up 9.0% year-over-year.
Long-term revenue has been compounding at 6.6% annually over 10 years.
The company is profitable, with a net margin of 11.9% and net income of ₹161 Cr.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Indraprastha Medical Corporation Ltd..